Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Bone Diseases 1

Interventions

daratumumab 2siltuximab 1sargramostim 1elotuzumab 1PVX-410 vaccine 1Monatide (IMS 3015) 1Lenalidomide 1IPH-2101 1Emulsions 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Smoldering Multiple Myeloma × BHQ880 × Clear all
NCT01302886 2020-12-17

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Novartis

Phase 2 Completed
41 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡